Rocket Lab Corporation
RKLB
$71.92
-4.18%
Rocket Lab Corporation is an end-to-end space company operating in the Aerospace & Defense industry, designing and manufacturing the Electron and Neutron launch vehicles along with the Photon satellite platform and a broad suite of spacecraft components, serving civil, defense, and commercial markets across two reporting segments, Launch Services and Space Systems. The company has established itself as the leading dedicated small-launch provider outside of SpaceX, with a vertically integrated model that spans launch, satellite manufacturing, and on-orbit services, positioning it as a platform play on the broader space economy rather than a pure-play rocket company. The current investor narrative is dominated by the pending Iridium acquisition, funded through a roughly $1.9 billion equity raise that dilutes shareholders by approximately 5%, alongside the delayed first flight of the Neutron medium-lift rocket now potentially slipping into 2027. Bulls point to record revenue growth, a $397 million Space Force contract win, and a diversified backlog, while bears highlight a valuation exceeding 40 times revenue and execution risk on Neutron, making this a high-conviction, high-volatility name where sentiment swings sharply around launch milestones and capital raises.…
RKLB
Rocket Lab Corporation
$71.92
Related headlines
Investment Opinion: Should I buy RKLB Today?
The synthesized recommendation is Hold, reflecting a balanced view of Rocket Lab's exceptional growth potential against its extreme valuation and execution risks. The analyst consensus is Buy with a recommendation mean of 1.57 and an average target price of $109.15, implying 47.7% upside, but the stock's 61.5x sales multiple and negative free cash flow warrant caution. The core thesis is that Rocket Lab is a high-quality space platform with a $397 million Space Force contract and 62% revenue growth, but the current price already discounts flawless execution.
Supporting evidence includes the 61.99% year-over-year revenue growth in Q2 2026, gross margin expansion to 36.13% from 32.10% a year earlier, and a strong balance sheet with $1.75 billion in cash and a current ratio of 4.08. However, the PS ratio of 61.51 is far above the industry average of 1-3x for Aerospace & Defense, and free cash flow remains deeply negative at -$398.35 million TTM. The implied upside to the average analyst target is substantial, but the wide target range of $64 to $150 signals low conviction even among professionals.
The biggest risks that could invalidate the thesis are a further delay in Neutron's first flight beyond 2027, integration challenges with the Iridium acquisition, and continued cash burn requiring additional dilution. The rating would upgrade to Buy if the PS ratio compresses below 40x or if Neutron achieves a successful first flight, and downgrade to Sell if revenue growth decelerates below 30% or free cash flow fails to improve. Relative to its history, the PS ratio has ranged from 21x to over 273x, so the current 61.5x is above the low end but far below the peak, suggesting the stock is fairly valued to slightly overvalued given its growth prospects.
Sign up to view all
RKLB 12-Month Price Forecast
Rocket Lab presents a compelling long-term growth story with 62% revenue growth, expanding gross margins, and a strong balance sheet, but the valuation at 61.5x sales leaves little room for error. The Neutron delay to 2027 and Iridium integration risks are significant overhangs, and the stock's high beta of 2.612 means it will remain volatile. The analyst consensus is bullish, but the wide target range of $64 to $150 reflects deep uncertainty. I would upgrade to bullish if Neutron achieves a successful first flight and free cash flow turns positive, and downgrade to bearish if revenue growth decelerates below 30% or another equity raise is announced.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rocket Lab Corporation's 12-month outlook, with a consensus price target around $109.15 and implied upside of +51.8% versus the current price.
Average Target
$109.15
0 analysts
Implied Upside
+51.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$64 - $150
Analyst target range
Coverage is robust with 20 analysts following Rocket Lab, and the consensus recommendation is a Buy with a recommendation mean of 1.57 on a scale where 1 is Strong Buy and 5 is Strong Sell. The average price target of $109.15 implies roughly 47.7% upside from the current price of $73.92, a substantial gap that reflects analyst confidence in the Iridium acquisition and Neutron ramp despite recent price weakness. The distribution of institutional ratings is overwhelmingly constructive, with recent actions from B of A Securities (Buy), Citizens (Market Outperform), Cantor Fitzgerald (Overweight), Roth Capital (Buy), Craig-Hallum (Buy), and Needham (Buy), and KGI Securities upgrading to Outperform from Neutral in late July 2026. This is a decidedly bullish consensus, though the magnitude of the implied upside suggests analysts may be slow to mark down targets after the stock's sharp decline from its 52-week high. The target range is exceptionally wide, from a low of $64.00 to a high of $150.00, a spread of more than 2.3x that signals very high uncertainty about the company's trajectory. The high target of $150.00 essentially assumes a full recovery to the 52-week high and likely prices in successful Neutron first flight, smooth Iridium integration, and continued 60%+ revenue growth with a credible path to profitability. The low target of $64.00, which sits about 13% below the current price, appears to price in Neutron delays extending well into 2027, integration risk and dilution from the Iridium deal, and continued cash burn that forces further capital raises. The wide dispersion, combined with a beta of 2.612 and a short ratio of 2.61, indicates that even the professional community has low conviction on fair value, and investors should expect continued volatility as Neutron launch dates and Iridium closing milestones drive sharp revisions in either direction.
Bulls vs Bears: RKLB Investment Factors
The bull case rests on Rocket Lab's exceptional 62% revenue growth, expanding gross margins, strong balance sheet, and a $397 million Space Force contract that validates its vertical integration strategy. However, the bear case is equally compelling: a 61.5x sales valuation leaves no room for error, free cash flow is deeply negative at -$398 million TTM, and the Neutron delay to 2027 pushes profitability further out. Currently, the bear evidence carries more weight because the valuation premium is so extreme relative to peers and the company's own history, and the cash burn requires continued external financing. The single most important tension is whether Neutron's first flight occurs in 2027 as guided or slips further, as a successful launch would validate the growth narrative and justify the premium, while another delay could trigger severe multiple compression toward the analyst low target of $64.
Bullish
- Revenue growth accelerating at 62% YoY: Q2 2026 revenue of $234.07 million grew 61.99% from $144.50 million in Q2 2025, with sequential expansion from $179.65 million in Q4 2025 to $200.35 million in Q1 2026. This consistent double-digit sequential climb demonstrates strong demand across both Launch Services and Space Systems.
- Gross margin expansion signals operating leverage: Gross margin improved to 36.13% in Q2 2026 from 32.10% a year earlier and 27.81% in Q4 2024, reflecting better cost absorption and favorable mix. This 8.3 percentage point expansion over six quarters shows the business is scaling efficiently.
- Analyst consensus Buy with 47.7% upside: 20 analysts rate RKLB a Buy with a recommendation mean of 1.57, and the average price target of $109.15 implies 47.7% upside from the current $73.92. Recent actions from B of A, Citizens, Cantor Fitzgerald, and others remain overwhelmingly constructive.
- Fortress balance sheet with $1.75B cash: The current ratio of 4.08 and debt-to-equity of just 0.147 provide substantial financial flexibility, with $1.75 billion in cash after the $1.9 billion equity raise. This funds the Iridium acquisition and Neutron development without near-term solvency risk.
Bearish
- Extreme valuation at 61.5x sales: The PS ratio of 61.51 and EV/Sales of 51.99 are far above Aerospace & Defense peers that typically trade at 1-3x sales. Even high-growth defense tech names rarely exceed 10-15x, leaving little margin for error if growth disappoints.
- Deeply negative free cash flow and profitability: Q2 2026 free cash flow was -$137.34 million, with TTM FCF at -$398.35 million, and net margin remains -21.04%. The company depends on external financing, as evidenced by $708.62 million in net cash from financing in the quarter.
- Neutron first flight delayed to 2027: The Neutron medium-lift rocket's first flight may slip into 2027, delaying a key revenue catalyst and pushing profitability further out. This execution risk is central to the bear case and could trigger further multiple compression.
- Iridium acquisition dilution and integration risk: The $1.9 billion equity raise to fund the Iridium acquisition dilutes shareholders by approximately 5% and adds integration complexity. The deal's success is unproven and could distract management from core launch operations.
RKLB Technical Analysis
Rocket Lab is in a recovery phase within a broader, highly volatile uptrend, with the stock up 40.88% over the past year but sitting at $73.92, which is only about 32% of its 52-week range between a low of $37.57 and a high of $151.00. That positioning near the lower third of the annual range despite a positive 1-year return signals that the stock has surrendered most of its earlier gains from a parabolic run, leaving it in a wide consolidation zone rather than at momentum-driven highs. The 60.99% maximum drawdown underscores how violently this name can retrace, and the current level reflects a market that has repriced the equity lower after the May peak above $150. Recent momentum has turned sharply positive even as the medium-term trend remains weak: the stock is up 17.15% over the past month versus a 26.42% decline over three months, a clear divergence where short-term buyers are stepping in against a still-broken intermediate trend. Relative strength tells the same story, with 1-month relative strength of +16.56% against SPY contrasting with -29.76% over three months, suggesting the recent bounce is a mean-reversion rally off oversold conditions rather than a confirmed trend reversal. The 4.91% single-day gain on elevated volume of roughly 26.7 million shares reinforces that buyers are active, but the 3-month weakness warns that overhead supply remains heavy. Key technical levels are well defined: support sits near the 52-week low of $37.57, with intermediate support around the $58-$64 zone where the stock based in late July and early September, while resistance looms at the $100 psychological level and the $151.00 52-week high. A breakout above $100 would signal renewed institutional conviction and likely require a Neutron or Iridium catalyst, whereas a breakdown below $58 would confirm the downtrend and open the door to retesting the annual low. With a beta of 2.612, the stock is roughly 2.6 times as volatile as the S&P 500, meaning position sizing must be dramatically smaller than a market-weight allocation to avoid disproportionate portfolio risk.
Beta
2.94
2.94x market volatility
Max Drawdown
-61.0%
Largest decline past year
52-Week Range
$38-$151
Price range past year
Annual Return
+16.9%
Cumulative gain past year
| Period | RKLB Return | S&P 500 |
|---|---|---|
| 1m | +11.9% | +0.9% |
| 3m | -12.9% | +3.4% |
| 6m | +5.7% | +14.4% |
| 1y | +16.9% | +16.2% |
| ytd | -5.4% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RKLB Fundamental Analysis
Rocket Lab's revenue trajectory is unambiguously strong, with Q2 2026 revenue of $234.07 million representing 61.99% year-over-year growth from $144.50 million in Q2 2025, capping a multi-quarter acceleration from $122.57 million in Q1 2025 and $155.08 million in Q3 2025. The sequential climb from $179.65 million in Q4 2025 to $200.35 million in Q1 2026 and then $234.07 million in Q2 2026 shows consistent double-digit sequential expansion, and the segment mix of $127.49 million in Product revenue versus $72.86 million in Service revenue confirms that hardware and spacecraft systems, not just launch fees, are driving the top line. This diversification is the core of the investment case, as it reduces dependence on any single launch cadence and positions the company to capture the broader space infrastructure buildout. Profitability remains the key weakness: Q2 2026 net income was -$49.26 million with a net margin of -21.04%, though this is a marked improvement from -$66.41 million and a -45.96% net margin in Q2 2025. Gross margin has expanded meaningfully to 36.13% in Q2 2026 from 32.10% a year earlier and 27.81% in Q4 2024, reflecting better cost absorption and mix, but operating margin is still deeply negative at -24.57% as R&D spending of $82.43 million and SG&A of $59.66 million continue to outpace gross profit of $84.58 million. The company is not yet profitable, and the path to breakeven depends on scaling Neutron and integrating Iridium, but the narrowing losses and rising gross margin show genuine operating leverage emerging. The balance sheet is a source of strength: the current ratio stands at 4.08 and the debt-to-equity ratio is a modest 0.147, while cash at the end of Q2 2026 reached $1.75 billion following the large equity raise. However, free cash flow remains deeply negative at -$137.34 million in Q2 2026 and -$398.35 million on a trailing-twelve-month basis, with operating cash flow of -$111.29 million and capital expenditures of $26.05 million, meaning the company is still burning cash and depends on external financing, as evidenced by $708.62 million in net cash from financing in the quarter. ROE of -11.51% and ROA of -4.62% confirm that capital is not yet generating positive returns, so the investment case rests on future cash generation rather than current financial productivity.
Quarterly Revenue
$234066000.0B
2026-06
Revenue YoY Growth
+62.0%
YoY Comparison
Gross Margin
36.1%
Latest Quarter
Free Cash Flow
$-398353000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RKLB Overvalued?
Because Rocket Lab's trailing net income is negative, the PE ratio is not meaningful at -188.54, and the appropriate primary metric is the price-to-sales ratio, which stands at an extremely elevated 61.51 on a trailing basis. The forward PE of 1,369.14 is technically positive only because analysts model a swing to profitability with estimated EPS of $0.882, but that figure implies a near-100% margin expansion from current loss levels and should be treated with heavy skepticism. The gap between the negative trailing PE and the enormous forward PE tells the real story: the market is pricing in a dramatic inflection to profitability that has not yet materialized, leaving little margin for error. On a peer basis, Rocket Lab's PS of 61.51 and EV/Sales of 51.99 are far above typical Aerospace & Defense multiples, where established primes often trade in the 1-3x sales range and even high-growth defense technology names rarely exceed 10-15x. The PB ratio of 21.50 further illustrates the premium, reflecting a market cap of roughly $37-44 billion against a relatively small revenue base of about $800 million annualized. This premium can only be justified by Rocket Lab's superior growth rate of 62% year-over-year and its unique position as a vertically integrated space platform, but the spread versus peers is so wide that any growth disappointment would likely trigger severe multiple compression. Historically, the stock's PS ratio has ranged from about 21x in mid-2024 to over 273x in Q2 2026 on a quarterly annualized basis, and the current 61.51x sits well above the low end of that band but far below the peak, suggesting the market has already de-rated the stock substantially from its most euphoric levels. The PB ratio of 21.50 is near the upper end of its historical range, which historically has oscillated between roughly 2.5x and 33x, indicating that while the valuation has cooled from extremes, it remains expensive relative to the company's own history and offers limited valuation support if fundamentals deteriorate.
PE
-188.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-234.4x
Enterprise Value Multiple
Investment Risk Disclosure
Rocket Lab faces significant financial and operational risks, primarily stemming from its unprofitable operations and heavy cash burn. Q2 2026 net income was -$49.26 million with a net margin of -21.04%, and free cash flow was -$137.34 million, contributing to a TTM FCF of -$398.35 million. The company relies on external financing, as shown by $708.62 million in net cash from financing in Q2 2026, and while the current ratio of 4.08 and debt-to-equity of 0.147 provide a cushion, continued losses could force further dilutive raises. Additionally, revenue concentration in the Launch Services segment and dependence on government contracts like the $397 million Space Force award introduce earnings volatility if contract timing shifts.
Market and competitive risks are amplified by Rocket Lab's premium valuation and high beta. The PS ratio of 61.51 and EV/Sales of 51.99 are far above Aerospace & Defense peers, leaving the stock vulnerable to multiple compression if growth decelerates or sentiment shifts. With a beta of 2.612, the stock is 2.6 times as volatile as the S&P 500, and the 60.99% maximum drawdown illustrates the severity of potential declines. Competitive threats from SpaceX and other launch providers, regulatory hurdles, and the capital-intensive nature of space infrastructure could pressure margins and delay Neutron's commercialization, as highlighted by recent news of the Neutron delay to 2027.
The worst-case scenario involves a chain of events where Neutron's first flight slips beyond 2027, the Iridium integration falters, and cash burn accelerates, forcing another dilutive equity raise. This could drive the stock toward its 52-week low of $37.57, representing a 49.2% decline from the current price of $73.92, or to the analyst low target of $64.00, a 13.4% drop. Given the 60.99% max drawdown, a retest of the annual low is plausible in a severe downturn, and investors could lose nearly half their capital if these risks materialize.
FAQ
The most severe risk is execution risk on Neutron, which has been delayed to potentially 2027, and any further slippage could trigger a sharp sell-off. Financial risk is also high, with free cash flow of -$398.35 million TTM and net margin of -21.04%, requiring external financing that could dilute shareholders further. Competitive risk from SpaceX and other launch providers could pressure pricing and market share, while regulatory and geopolitical risks could disrupt government contracts. Macro risk is amplified by the stock's beta of 2.612, meaning it is highly sensitive to market downturns, and the 60.99% maximum drawdown shows how quickly value can evaporate. Ranked by severity: execution risk, financial risk, competitive risk, and macro risk.
The 12-month forecast has three scenarios: a bull case with 25% probability targeting $130-$150, a base case with 50% probability targeting $95-$115, and a bear case with 25% probability targeting $55-$70. The base case is most likely, assuming Neutron's first flight occurs in late 2027, Iridium integrates smoothly, and revenue grows 40-50%, aligning with the analyst average target of $109.15. The bull case requires a successful Neutron launch and accretive Iridium contribution, while the bear case involves further delays and cash burn forcing dilution. The key assumption behind the base case is that execution meets tempered expectations without major surprises.
Rocket Lab appears overvalued on traditional metrics, with a PS ratio of 61.51 and EV/Sales of 51.99, far above the Aerospace & Defense industry average of 1-3x sales. The PB ratio of 21.50 is also near the upper end of its historical range of 2.5x to 33x, and the forward PE of 1,369.14 implies a near-100% margin expansion that is highly uncertain. However, the stock has de-rated from its peak PS of over 273x in Q2 2026, and the current multiple is well below that extreme. The market is pricing in flawless execution of Neutron and Iridium, with 62% revenue growth expected to continue. If growth decelerates or execution stumbles, the valuation could compress significantly toward the analyst low target of $64, representing 13.4% downside.
Rocket Lab is a high-risk, high-reward stock that may be a good buy for investors with a long-term horizon and high risk tolerance, but it is not suitable for conservative portfolios. The analyst consensus is Buy with an average target of $109.15, implying 47.7% upside, and revenue grew 61.99% year-over-year in Q2 2026. However, the stock trades at 61.5x sales, has negative free cash flow of -$398.35 million TTM, and carries a beta of 2.612, meaning it is 2.6 times as volatile as the S&P 500. The biggest downside risk is a Neutron delay beyond 2027 or another dilutive capital raise, which could send the stock toward the analyst low target of $64 or the 52-week low of $37.57. For those who can stomach volatility and believe in the space economy, RKLB offers a unique platform play, but position sizing should be conservative.
Rocket Lab is better suited for long-term investment, with a suggested minimum holding period of 3-5 years to ride out the extreme volatility and allow Neutron and Iridium to mature. The company is in a high-growth phase with 62% revenue growth, but it is not yet profitable and pays no dividend, so returns depend on capital appreciation. The beta of 2.612 and 60.99% max drawdown make it unsuitable for short-term trading unless one is a highly active trader with strict risk management. Earnings visibility is low due to launch schedule variability, so long-term investors should focus on the secular space economy trend and the company's vertical integration strategy. Short-term traders could exploit volatility around launch milestones, but the risk of sharp reversals is high.